Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy

Objective: In order to obtain a neutralizable antithrombotic, a chimeric molecule (SSR126517E) containing the sequence of a long‐lasting antithrombin (AT)‐dependent anti‐factor Xa pentasaccharide, idraparinux, linked to a biotin molecule was synthesized and tested for anticoagulant and antithromboti...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thrombosis and haemostasis 2008-10, Vol.6 (10), p.1697-1706
Main Authors: SAVI, P., HERAULT, J. P., DUCHAUSSOY, P., MILLET, L., SCHAEFFER, P., PETITOU, M., BONO, F., HERBERT, J. M.
Format: Article
Language:English
Subjects:
Animals
Anticoagulants - pharmacokinetics
Antithrombin III - metabolism
antithrombotic
avidin
Avidin - administration & dosage
Avidin - pharmacology
Biotinylation
Factor Xa Inhibitors
Fibrinolytic Agents - pharmacokinetics
Mice
neutralization
Oligosaccharides - chemistry
Oligosaccharides - pharmacokinetics
Oligosaccharides - therapeutic use
Rats
Thrombin - biosynthesis
Thrombosis - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: In order to obtain a neutralizable antithrombotic, a chimeric molecule (SSR126517E) containing the sequence of a long‐lasting antithrombin (AT)‐dependent anti‐factor Xa pentasaccharide, idraparinux, linked to a biotin molecule was synthesized and tested for anticoagulant and antithrombotic activity. Methods: SSR126517E was tested in several models in vitro and in vivo for its pharmacological properties as well as its ability to be neutralized by avidin. Results: SSR126517E displayed exactly the same properties as idraparinux. In vitro, SSR126517E had a very high affinity for AT (Kd 
ISSN:1538-7933
1538-7836
DOI:10.1111/j.1538-7836.2008.03089.x